Seattle's Accelerator Adds PPD as Investor | GenomeWeb
NEW YORK (GenomeWeb News) – Seattle-based biotechnology investment and management company Accelerator Corporation said today that drug discovery contract research organization PPD has joined as the sixth investor in its Accelerator III investment vehicle.
 
Accelerator provides resources to biotech companies, including capital financing, facilities, scientific and technical expertise and support, as well as business management and support.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.